OncoC4 Initiates First Phase 1/2 Clinical Trial for Alzheimer's Disease Therapy ONC-841 OncoC4 Inc. has started dosing the first participant in its Phase 1/2 trial of ONC-841, an innovative Alzheimer’s treatment, after regulatory approval.

OncoC4 Initiates First Phase 1/2 Clinical Trial for Alzheimer's Disease Therapy ONC-841 #USA #Rockville #Alzheimer's #OncoC4 #ONC-841

China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer OncoC4 announces that China's NMPA has granted Breakthrough Therapy Designation for Gotistobart (BNT316/ONC-392) aimed at treating squamous non-small cell lung cancer, enhancing prospects for patients facing limited options.

China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer #China #Rockville #OncoC4 #Gotistobart #BNT316

OncoC4 Secures $50 Million in Series B Funding to Enhance Cancer Treatments OncoC4 has successfully closed a Series B funding round, raising nearly $50 million to further the development of innovative cancer therapies, marking a significant milestone for the company.

OncoC4 Secures $50 Million in Series B Funding to Enhance Cancer Treatments #USA #Rockville #cancer_therapies #Series_B_Funding #OncoC4